Patents Examined by Dameron L. Jones
  • 5-arylsulfonyl indoles useful for treating disease
    Patent number: 6565829
    Abstract: The invention provides derivatives of 5-arylsulfonyl indole and 5-arylsulfonyl indoline compounds which may be in the form of pharmaceutical acceptable salts or compositions that are useful in treating central nervous system diseases such as anxiety and depression. The invention also includes intermediates and processes to make the compounds, isotopically-labeled forms of the compounds and the use of the isotopically labeled forms of the compounds to perform nuclear magnetic resonance imaging and positron emission tomography.
    Type: Grant
    Filed: August 1, 2002
    Date of Patent: May 20, 2003
    Assignee: Pharmacia & Upjohn Company
    Inventor: Jian-Min Fu
  • Macrocyclic chelants for metallopharmaceuticals
    Patent number: 6565828
    Abstract: This invention relates to new macrocyclic chelants and metal chelates thereof, methods of preparing the chelants and metal chelates, and pharmaceutical compositions comprising the macrocyclic chelants and metal chelates. This invention relates particularly to the use of the new metal chelates as contrast agents in X-ray or CT, MRI imaging, and radiopharmaceuticals for the diagnosis of cardiovascular disorders, infectious disease and cancer. This invention also relates to new bifunctional chelants (BFCs) for attaching diagnostic metals and therapeutic isotopes to target-specific biomolecules such as proteins, peptides, peptidomimetics, and non-peptide receptor ligands. In addition, the macrocyclic chelants are useful for heavy metal detoxification.
    Type: Grant
    Filed: April 5, 2001
    Date of Patent: May 20, 2003
    Assignee: Bristol-Myers Squibb Company
    Inventor: Shuang Liu
  • Desmethylselegiline enantiomers and their use to treat drug withdrawal symptoms
    Patent number: 6562364
    Abstract: The application is directed to the treatment of one or more symptoms associated with drug withdrawal by administering desmethylselegiline.
    Type: Grant
    Filed: March 13, 2001
    Date of Patent: May 13, 2003
    Assignee: Somerset Pharmaceuticals, Inc.
    Inventors: Anthony R. DiSanto, Cheryl D. Blume
  • Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy
    Patent number: 6562319
    Abstract: Radiolabeled epidermal growth factor receptor tyrosine kinase (EGFR-TK) irreversible inhibitors and their use as biomarkers for medicinal radioimaging such as Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) and as radiopharmaceuticals for radiotherapy are disclosed.
    Type: Grant
    Filed: March 12, 2001
    Date of Patent: May 13, 2003
    Assignees: Yissum Research Development Company of the Hebrew University of Jerusalem, Hadasit Medical Research Services and Development Ltd.
    Inventors: Eyal Mishani, Iris Ben-David, Yulia Rozen, Gluseppina Ortu, Alexander Levitzki
  • Particular agents
    Patent number: 6562318
    Abstract: A novel means of pharmaceutical delivery for therapy or prophylaxis or to assist surgical or diagnostic operations on the living body is provided by agents which undergo neuronal endocytosis and axonal transport following pharmaceutical administration into vascularized, peripherally innervated tissue, e.g., intramuscular injections of a nerve adhesion molecule comprising a physiologically active substance or a diagnostic marker.
    Type: Grant
    Filed: July 26, 1999
    Date of Patent: May 13, 2003
    Assignee: Syngenix Limited
    Inventor: Aaron Gershon Filler
  • Cosmetic compositions
    Patent number: 6562322
    Abstract: A cosmetic composition having improved transfer resistance comprising: a) from about 0.1-60% by weight of trimethylated silica, b) from about 0.1-60% by weight of a volatile solvent having a viscosity of 0.5 to 100 centipoise at 25° C., c) 0.1-60% by weight of a nonvolatile oil having a viscosity of 200 to 1,000,000 centipoise at 25° C. d) 0.1-80% of a cosmetically acceptable carrier.
    Type: Grant
    Filed: June 25, 2002
    Date of Patent: May 13, 2003
    Assignee: Revlon Consumer Products Corporation
    Inventors: Hernando Brieva, Julio Gans Russ, Ida Marie Sandewicz
  • Vitronectin receptor antagonist pharmaceuticals
    Patent number: 6558649
    Abstract: The present invention describes novel compounds of the formula: (Q)d—Ln—Ch, useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The present invention further provides novel compounds useful for imaging atherosclerosis, restenosis, cardiac ischemia and myocardial reperfusion injury. The present invention still further provides novel compounds useful for the treatment of rheumatoid arthritis. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety.
    Type: Grant
    Filed: December 17, 1999
    Date of Patent: May 6, 2003
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Edward H. Cheesman, Michael Sworin, Milind Rajopadhye
  • Targeted combination immunotherapy of cancer and infectious diseases
    Patent number: 6558648
    Abstract: The present invention is directed to methods for treating cancer wherein more than one therapeutic agent is used, with each of the therapeutic agents having different tumor-killing capabilities, and wherein the therapeutic agents are delivered to the tumor sites using combined targeting and pre-targeting methods. The methods of the present invention achieve good tumor to non-tumor ratios of the therapeutic agents, and are effective for cancer therapy.
    Type: Grant
    Filed: June 20, 2000
    Date of Patent: May 6, 2003
    Assignee: Immunomedics, Inc.
    Inventors: Gary L. Griffiths, Hans J. Hansen, David M. Goldenberg
  • Lipase inhibiting polymers
    Patent number: 6558657
    Abstract: The invention features a method for treating obesity in a patient by administering to the patient a polymer that has been substituted with one or more groups that inhibit lipases, which are enzymes responsible for the hydrolysis of fat. The invention further relates to the polymers employed in the methods described herein as well as novel intermediates and methods for preparing the polymers.
    Type: Grant
    Filed: November 16, 2000
    Date of Patent: May 6, 2003
    Assignee: GelTex Pharmaceuticals, Inc.
    Inventors: W. Harry Mandeville, III, Molly Kate Boie, Venkata R. Garigapati
  • Enhancement of cellular gallium uptake
    Patent number: 6558650
    Abstract: A method for improving cellular gallium uptake (particularly of tumor cells) by exposing cells to a nifedipine photodegradation product, or an analog thereof. In particular embodiments, the gallium uptake enhancer is selected from the group of A-B and formula (I), wherein A is a pyridine and B is a nitrosophenyl, and n=1-10. In yet other embodiments, the uptake enhancer is formula (II), wherein R1-9 are independently selected from the group consisting of H, halogen, haloalkyl, NO2, NO, SO2, a C1-6 alkyl, a COOR10 wherein R10 is H or C1-6 alkyl, and an —OR11 wherein R11 is H or C1-6 alkyl; wherein at least one of R5 and R7 is NO. The uptake enhancers are particularly useful in imaging tumors, using such techniques as gallium scanning, in which the dose of the gallium isotope can be decreased or its imaging efficiency improved.
    Type: Grant
    Filed: October 6, 2000
    Date of Patent: May 6, 2003
    Assignee: Oregon Health and Science University
    Inventors: Kathryn A. Morton, Jean-Baptiste Roullet
  • Tuftsin metallopeptide analogs and uses thereof
    Patent number: 6551574
    Abstract: Tuftsin receptor-specific peptides, peptidomimetics and peptide-like constructs are provided, particularly for use in biological, pharmaceutical and radiopharmaceutical applications, in which the peptide, peptidomimetic or construct is conformationally fixed on complexation of the metal ion-binding portion thereof with a metal ion, resulting in a peptide, peptidomimetic or construct with increased affinity for the tuftsin receptor.
    Type: Grant
    Filed: August 30, 1999
    Date of Patent: April 22, 2003
    Assignee: Rhomed Incorporated
    Inventor: Shubh D. Sharma
  • Dopamine transporter imaging agents
    Patent number: 6548041
    Abstract: Radiopharmaceutical compounds are disclosed. A tropane compound is linked through the N atom at the 8-position to a chelating ligand capable of complexing technetium or rhenium to produce a neutral labeled complex that selectively binds to the dopamine transporter over the serotonin transporter with a ratio of 10 or more. These compounds can be prepared as separate diastereoisomers as well as a mixture of diastereoisomers. Also disclosed are radiopharmaceutical kits for preparing the labeled radiopharmaceutical compounds.
    Type: Grant
    Filed: May 10, 2000
    Date of Patent: April 15, 2003
    Assignees: Organix, Inc., President and Fellow of Harvard College, The General Hospital Corporation
    Inventors: Peter C. Meltzer, Paul Blundell, Bertha K. Madras, Alan J. Fischman, Alun G. Jones, Ashfaq Mahmood
  • Diagnostic and contrast agent
    Patent number: 6544496
    Abstract: The present invention relates to a method of contrast enhanced ultrasonic diagnostic imaging comprising administering to a subject a contrast enhancing amount of spherical particles comprising a matrix enclosing a gaseous contrast agent which reflects sound waves, said matrix being a biocompatible, biodegradable, non-immunogenic non-polyamino acid synthetic polymer; and generating an ultrasonic image of said subject. The polymer may be selected from the group consisting of carbohydrates, carbohydrate derivatives and non-polyamino acid synthetic polymers.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: April 8, 2003
    Assignee: Amersham Health AS
    Inventor: Ulf Schröder
  • Skin care composition
    Patent number: 6544531
    Abstract: There are provided compositions which include a retinoid and preferably retinol; a dermatologically active acid; and a volatile base, such as ammonium hydroxide. Another embodiment of the invention includes compositions comprising a retinoid and preferably retinol; a dermatologically active acid; a volatile base; and a second neutralizing agent. There are also provided compositions which include a retinoid, a neutralized ammonium salt of a dermatologically active acid, and optionally a neutralized salt, other than ammonium salt, of an acid. Further provided are methods for reducing fine lines, wrinkles, skin roughness, and pore size and for increasing the clarity of a skin surface, cellular turnover, skin radiance, skin smoothness, skin permeation or collagen synthesis in a mammal in need thereof. Compositions as described above are administered topically to the skin of the animal.
    Type: Grant
    Filed: November 9, 1999
    Date of Patent: April 8, 2003
    Assignee: Johnson & Johnson Products, Inc.
    Inventors: Curtis A. Cole, Laura E. Flack, Claudia Kaminski, Victoria Van Leeuwen
  • Methods for detecting lesions in dense breast tissue using LHRH antagonists
    Patent number: 6540979
    Abstract: Improved methods for detecting lesions in dense breast tissue are disclosed. The methods of the invention generally feature administration to a subject of an LHRH antagonist in an amount and for a period of time sufficient to reduce the density of breast tissue prior to generating an image of the breast tissue, for example by mammography, to detect a lesion in the breast tissue. Packaged formulations for reducing breast density in a subject prior to generating an image of the subject's breast tissue, comprising an LHRH antagonist packaged with instructions for using the LHRH antagonist to reduce breast density in a subject prior to imaging the breast tissue, are also disclosed.
    Type: Grant
    Filed: January 18, 2001
    Date of Patent: April 1, 2003
    Assignee: Praecis Pharmaceuticals, Inc.
    Inventor: Marc B. Garnick
  • Method of detecting endometriosis
    Patent number: 6540980
    Abstract: Kits for detecting and treating endometriosis are provided, which contain a targeting molecule comprising an eosinophil peroxidase-binding component. Methods of detecting and treating endometriosis using eosinophil peroxidase-specific targeting molecules are also provided Targeting molecules comprise an eosinophil peroxidase-binding component and an accessory component; the accessory component comprising an agent conferring detectability or a therapeutic effect.
    Type: Grant
    Filed: March 31, 2000
    Date of Patent: April 1, 2003
    Assignee: Center for Molecular Medicine and Immunology
    Inventors: Rosalyn D. Blumenthal, David M. Goldenberg, Michael Samoszuk
  • Method for reducing radiation toxicity
    Patent number: 6540976
    Abstract: Intestinal radiation injury (radiation enteropathy) is an important dose limiting factor during treatment of abdominal and pelvic tumors and a major determinant in the quality of life among cancer survivors. Inflammatory and fibrogenic mediators released by mucosal inflammatory cells are involved in the mechanisms of injury. Treatment with Orazipone decreases the toxicity following Gy radiation dose, as measured by histopathologic scoring, TGF-&bgr;, IL-1&agr;, and ED-2 macrophage antigen immunoreactivity.
    Type: Grant
    Filed: September 23, 1998
    Date of Patent: April 1, 2003
    Assignee: The Board of Trustees of the University of Arkansas
    Inventors: Martin Hauer-Jensen, Paivi Aho
  • Inhibitors of the bitter taste response
    Patent number: 6540978
    Abstract: The present invention relates to methods for identifying inhibitors of the bitter taste response, and by methods of using such inhibitors to either block the perception of bitterness and/or promote the perception of a sweet taste. The inhibitors of the invention may be used as flavor enhancers in foods and pharmaceuticals. The methods of the invention may further be used to characterize the gustatory perception of novel tastants.
    Type: Grant
    Filed: December 22, 1999
    Date of Patent: April 1, 2003
    Assignee: Mount Sinai School of Medicine of New York University
    Inventors: Robert F. Margolskee, Ding Ming
  • Pharmaceuticals for the imaging of angiogenic disorders
    Patent number: 6537520
    Abstract: The present invention describes novel compounds of the formula: (Q)d—Ln—Ch, useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety. The imageable moiety is a gamma ray or positron emitting radioisotope, a magnetic resonance imaging contrast agent, an X-ray contrast agent, or an ultrasound contrast agent.
    Type: Grant
    Filed: June 21, 2000
    Date of Patent: March 25, 2003
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Milind Rajopadhye, D. Scott Edwards, John A. Barrett, Alan P. Carpenter, Jr., Thomas D. Harris, Stuart J. Heminway, Shuang Liu, Prahlad R. Singh
  • Polymeric contrast agents for characterizing tumor angiogenesis in medicalimaging
    Patent number: 6537521
    Abstract: In a method for characterizing the angiogenesis status of a tumor in a living subject, timed magnetic resonance images of the subject into whom a reptating polymer contrast agent containing chelating diethylentriaminepentacetic acid dosed with gadolinum has been introduced are obtained. At least two images taken at different times are compared in order to determine the percentage image enhancement in a tumor region of interest. A contrast agent including a reptating polymer containing technetium-99 is used with a nuclear medicine version of this technique.
    Type: Grant
    Filed: February 23, 2001
    Date of Patent: March 25, 2003
    Assignee: General Electric Company
    Inventor: Egidijus Edward Uzgiris